Trial Profile
Tolerance and Efficacy of Rituximab in Sjogren's Disease.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Acronyms TEARS
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 30 Oct 2013 Post-hoc analysis for the impact of various endpoints on the sample size presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.